drugset / Trial / NCT01617096

Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women

NCT01617096 ↗

RandomizedParallel-groupDouble-blindPrevention

Summary

This is a double-blind, randomised, placebo-controlled study to assess the safety and efficacy of a silicone elastomer vaginal matrix ring.

Timeline

Start
2012-07-24
Primary completion
2015-07-03
Completion
2015-12

Outcome

Met primary endpoint

paper The incidence of HIV-1 infection in the dapivirine group was lower by 27% (95% confidence interval [CI], 1 to 46; P=0.046) PMID 26900902 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject dapivirine Small molecule 25 mg Other